Navigation Links
Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
Date:11/8/2011

RICHMOND, Calif., Nov. 8, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 11:00 am ET on Tuesday, November 15, 2011 at the Lazard Capital Markets 8th Annual Healthcare Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. Sangamo has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
3. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
4. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
5. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
6. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
7. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
8. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
9. Sangamo Announces Pricing of Public Offering of Common Stock
10. Sangamo Announces Public Offering of Common Stock
11. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight Against ... Cancer Research (OICR) are pleased to report that Fusion ... financing, with Johnson & Johnson Innovation – JJDC, Inc. ... venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, ... ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and ... or in healthcare facilities during periods of rest. A lightweight, non-invasive monitor is ...
(Date:2/23/2017)... Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies ... Marbán, Ph.D, president and chief executive officer, is scheduled to ... Cowen and Company 37th Annual Health Care Conference Tuesday, March ... 29th Annual ROTH Conference Tuesday, ... Dana Point, CA ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... announced that is has acquired Kendall Research Systems, LLC (KRS) clinical ... (MIT) that develops neural interface technology for research and clinical applications. The terms ...
Breaking Biology Technology:
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
(Date:1/26/2017)... -- Crossmatch, a leading provider of security and identity management ... fraud, waste and abuse in assistance operations around the ... Disaster Relief conference in Panama City ... foreign assistance organizations throughout Latin America ... largely unacknowledged problem in the foreign assistance and disaster ...
Breaking Biology News(10 mins):